Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Journal for Immunotherapy of Cancer
|
October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Journal for Immunotherapy of Cancer
|
April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Nizar M Tannir, Daniel C Cho, Adi Diab, et al.
Investigational New Drugs
|
November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.
European Urology
|
June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.
Cancer
|
November 16, 2021
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
Hamid Emamekhoo, Mark R Olsen, Bradley C Carthon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Journal for Immunotherapy of Cancer
|
August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Nature Medicine
|
April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Journal for Immunotherapy of Cancer
|
October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Journal for Immunotherapy of Cancer
|
April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Nizar M Tannir, Daniel C Cho, Adi Diab, et al.
Investigational New Drugs
|
November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.
European Urology
|
June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.
Cancer
|
November 16, 2021
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
Hamid Emamekhoo, Mark R Olsen, Bradley C Carthon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab, Scott S Tykodi, Gregory A Daniels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Journal for Immunotherapy of Cancer
|
August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Nature Medicine
|
April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
Page
of 5